Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

49.86 +1.93 (+4.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 980,419
Open 50.00
Bid (Size) 49.84 (1)
Ask (Size) 51.25 (1)
Prev. Close 47.93
Today's Range 48.85 - 50.98
52wk Range 19.83 - 94.75
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-18.62%
-18.62%
1 Month
-15.49%
-15.49%
3 Month
-24.74%
-24.74%
6 Month
+2.91%
+2.91%
1 Year
-41.12%
-41.12%

More News

Read More
The 5 Stocks Most Sold By Insiders This Year
Via MarketBeat
Expert Ratings For Apellis Pharmaceuticals
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
Via Benzinga
Peering Into Apellis Pharmaceuticals's Recent Short Interest
Via Benzinga
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings)
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
Here's How Much You Would Have Made Owning Apellis Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
$1000 Invested In Apellis Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Via MarketBeat
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.